Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Current Deferred Revenue (2016 - 2026)

Biomerica's Current Deferred Revenue history spans 14 years, with the latest figure at $30000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 45.45% to $30000.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $30000.0, a 45.45% decrease, with the full-year FY2025 number at $55000.0, down 35.29% from a year prior.
  • Current Deferred Revenue hit $30000.0 in Q1 2026 for Biomerica, roughly flat from $30000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for BMRA hit a ceiling of $3.2 million in Q1 2022 and a floor of $30000.0 in Q4 2025.
  • Historically, Current Deferred Revenue has averaged $255623.6 across 5 years, with a median of $60000.0 in 2023.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 97.72% in 2022 and later skyrocketed 41.67% in 2024.
  • Tracing BMRA's Current Deferred Revenue over 5 years: stood at $49013.0 in 2022, then rose by 22.42% to $60000.0 in 2023, then skyrocketed by 41.67% to $85000.0 in 2024, then tumbled by 64.71% to $30000.0 in 2025, then changed by 0.0% to $30000.0 in 2026.
  • Business Quant data shows Current Deferred Revenue for BMRA at $30000.0 in Q1 2026, $30000.0 in Q4 2025, and $54000.0 in Q3 2025.